ALCAM and leukemia: The importance of CD166 in leukaemia has been well demonstrated by a study in which blocking CD166-ILT3 interactions with an ILT3-Fc dramatically reduced proliferation and growth of leukaemia cells and increased the survival of tumour-bearing mice (in both H9 and Jakart models) [28].